Philadelphia Chromosome-Negative Myeloproliferative Disorders: Biology and Treatment

Biology of Blood and Marrow Transplantation

Volumn 13, Issue SUPPL. 1, 2007, Pages 64-72

  Hoffman, Ronald ^a,c   Prchal, Josef T ^b,c   Samuelson, Scott ^b,c   Ciurea, Stefan O ^a,c   Rondelli, Damiano ^a,c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Myeloproliferative Disorder Research Consortium   (United States)

Author keywords

Essential thrombocythemia; Idiopathic myelofibrosis; JAK2; Myeloproliferative disorders; Polycythemiavera; Stem cell transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; CYCLOPHOSPHAMIDE; DANAZOL; ERYTHROPOIETIN; FLUDARABINE; HYDROXYUREA; INTERFERON; JANUS KINASE 2; LENALIDOMIDE; MELPHALAN; PEGINTERFERON; STAT PROTEIN; THALIDOMIDE; THIOTEPA; THROMBOPOIETIN RECEPTOR; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BLOOD TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG TOXICITY; EXTRAMEDULLARY HEMATOPOIESIS; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; LOW DRUG DOSE; MEDICAL DOCUMENTATION; MONOTHERAPY; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; PLURIPOTENT STEM CELL; POLYCYTHEMIA VERA; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT OUTCOME; VEIN OCCLUSION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; SIGNAL TRANSDUCTION;

EID: 33846028528     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.11.003     Document Type: Article

References (68)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 6 (1951) 372-375
2. James C., Ugo V., Le Couedic J.P., et al. A unique JAK2 mutation leading to constitute signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
3. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270 [epub ahead of print]
4. Prchal J.F., and Axelrad A.A. Bone marrow responses in polycythemia vera. N Engl J Med 290 (1974) 1382 (letter)
5. Correa P.N., Eskinazi D., and Axelrad A.A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 83 (1994) 99-112
6. Dai C.H., Krantz S.B., Dessypris E.N., et al. Polycythemia vera, II: hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocytes macrophage colony-stimulating factor. Blood 80 (1992) 891-899
7. Kralovics R., Guan Y., and Prchal J.T. Differences in gene expression between normal and polycythemia vera CD34 cells. Blood 86 (1995) 733a (abstr.)
8. Chiba S., Takahashi T., Takeshita K., et al. Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera. Blood 90 (1997) 97-104
9. Temerinac S., Klippel S., Strunck E., et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95 (2000) 2569-2576
10. Silva M., Richard C., Benito A., et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338 (1998) 564-567
11. Dai C., and Krantz S.B. Increased expression of the INK4a/ARF locus in polycythemia vera. Blood 97 (2001) 3424-332
12. Sui X., Krantz S.B., and Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood 90 (1997) 651-657
13. Kralovics R., Guan Y., and Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30 (2002) 229-236
14. Ang S.O., and Prchal J.T. The polycythemia vera and other polycythemic disorders: biological aspects. In: Melo J.V., and Goldman J.M. (Eds). Myeloproliferative Diseases (2006), Springer-Verlag, New York 297-319
15. Huang L.J., Constantinescu S.N., and Lodish H.F. The N-terminal domain of Janus kinase 2 is required for golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8 (2001) 1327-1338
16. Ugo V., Marzac C., Teyssandier I., et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32 (2004) 179-187
17. Mnjoyan Z., Yoon D., Li J., et al. The effect of the JAK2 V617F mutation of PRV-1 expression. Haematologica 91 (2006) 411-412
18. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
19. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
20. Emanuel P., and Prchal J.T. The molecular basis of polycythemia vera unraveled?. The Hematologist 2 (2005) 1-2
21. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
22. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
23. Jelinek J., Oki Y., Gharibyan V., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
24. Tefferi A., Lasho T.L., Schwager S.M., et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106 (2006) 631-635
25. Popat U., Frost A., Liu E., et al. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107 (2006) 3486-3488
26. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) Jul 25 [epub ahead of print]
27. Wolanskyj A.P., Schwager S.M., McClure R.F., et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81 (2006) 159-166
28. Chim C.S., Kwong Y.L., Kwok-Wei Lie A., et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis and leukemia. Arch Intern Med 165 (2005) 2651-2658
29. Patel R.K., Lea N.C., Heneghan M.A., et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130 (2006) 2031-2038
30. Vardiman J.W., Brunning R.D., and Harris L.D. Chronic myeloproliferative diseases. In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). Introduction in Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon, France 17-19
31. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study. Lancet 366 (2005) 1995-1953
32. Campbell P.J., Baxter E.J., Beer P.A., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood (2006) Jul 27 [epub ahead of print]
33. Finazzi G., and Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 74 (2005) 489-495
34. Kiladjian J.J., Cassinat B., Turlure P., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood (2006) May 18 [epub ahead of print]
35. Finazzi G., Caruso V., Marchioli R., et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105 (2005) 2664-2670
36. Harrison C.N., Campbell P.J., Buck G., et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 (2005) 33-45
37. Xu M., Bruno E., Chao J., et al. The constitutive mobilization of bone marrow-repopulation cells into the peripheral blood in idiopathic myelofibrosis. Blood 105 (2005) 1699-1705
38. +, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 23 (2005) 5688-5695
39. + cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 105 (2005) 4508-4515
40. Rondelli D., Barosi G., Bacigalupo A., et al. Myeloproliferative Diseases Research Consortium. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105 (2005) 4115-4119
41. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
42. Dingli D., Schwager S.M., Mesa R.A., et al. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 106 (2006) 623-630
43. Dingli D., Schwager S.M., Mesa R.A., et al. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 106 (2006) 1985-1989
44. Anderson J., Sale G., Appelbaum F., et al. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 98 (1997) 1010-1016
45. Creemers G., Lowenberg B., and Hagenbeek A. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 82 (1992) 158-162
46. Singhal S., Powles R., Treleaven J., et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 16 (1995) 743-746
47. Przepiorka D., Giralt S., Khouri I., et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 57 (1998) 24-29
48. Guardiola P., Anderson J.E., Bandini G., et al., A European Group for Blood and Marrow Transplantation, Sociate Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto di Midollo Osseo and Fred Hutchinson Cancer Research Center Collaborative Study. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia. Blood 93 (1999) 2831-2838
49. Daly A., Song K., Nevill T., et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 32 (2003) 35-40
50. Deeg H.J., Gooley T.A., Flowers M.E., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
51. Byrne J.L., Beshti H., Clark D., et al. Induction of remission after donor leukocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogenic transplantation: evidence for a "graft vs myelofibrosis" effect. Br J Haematol 108 (2000) 430-433
52. Guardiola P., Anderson J.E., and Gluckman E. Myelofibrosis with myeloid metaplasia. N Engl J Med 343 (2000) 659-660 (letter)
53. Anderson J.E., Tefferi A., Craig F., et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myelofibrosis. Blood 98 (2001) 586-593
54. Barrett A.J., and Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia (2006) Jul 27 [epub ahead of print]
55. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99 (2002) 2255-2258
56. Kroger N., Zabelina T., Schieder H., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128 (2005) 690-697
57. + cells in idiopathic myelofibrosis. Am J Clin Pathol 123 (2005) 833-839
58. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6 (2000) 548-554
59. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002) 468-476
60. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
61. Chunduri S., Dobogai L., Peace D., et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 38 (2006) 477-482
62. Barosi G., Ambrosetti A., Buratti A., et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 7 (1993) 200-206
63. Tefferi A., Mesa R.A., Nagorney D.N., et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95 (2000) 2226-2233
64. Barosi G., Ambrosetti A., Centra A., et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 91 (1998) 3630-3636
65. Li Z., Gooley T., Applebaum F.R., et al. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 97 (2001) 2180-2181
66. Barosi G., Bordessoule D., Briere J., et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 106 (2005) 2849-2853
67. Tefferi A., Barosi G., Mesa R.A., et al., International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia. Blood 108 (2006) 1497-1503
68. Snyder D.S., Palmer J., Stein A.S., et al. Allogeneic Hematopoietic Cell Transplantation following Reduced Intensity Conditioning for Treatment of Myelofibrosis. Biol Blood Marrow Transplant 12 (2006) 1161-1168